Russell Investments Group
CTNM

Russell Investments Group’s Contineum Therapeutics CTNM Stock Holding History

Russell Investments Group’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-318
Closed -$2.22K – 3975
2025
Q1 		$2.22K Buy
+318
New +$2.89K ﹤0.01% 3499

Other funds holding CTNM

JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Russell Investments Group's CTNM Position: Q2 2025 in Review

Russell Investments Group sold out of Contineum Therapeutics (CTNM) in Q2 2025, closing a stake of 318 shares — an estimated $2.22K sold.

Russell Investments Group first reported a position in CTNM in Q1 2025 and held it in 1 quarter. The position peaked at $2.22K in Q1 2025. 70 funds tracked by Wall St. Rank hold CTNM as of Q2 2025.

  • Russell Investments Group reported no remaining Contineum Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Russell Investments Group sold 318 Contineum Therapeutics shares in Q2 2025, an estimated $2.22K.
  • Russell Investments Group first reported a position in Contineum Therapeutics in Q1 2025 and held it in 1 quarter.
  • Russell Investments Group's Contineum Therapeutics position peaked at $2.22K in Q1 2025.
  • 70 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2025.

Based on Russell Investments Group's 13F filing for Q2 2025, filed 13 Aug 2025.